7 withdrawn. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Withdrawn 7 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Thalassemia: new trials by email Literature Review of Thalassemia trials Research Report on Thalassemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID - Beta-Thalassemia | Phase 2 | Withdrawn | Vifor (International) Inc. | 2021-09-20 | 2022-11-10 | |
| SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias SP-420 - Iron Overload, Beta-Thalassemia | Phase 2 | Withdrawn | Abfero Pharmaceuticals, Inc | 2020-08-01 | 2020-10-05 | |
| Treatment of Iron Overload Requiring Chelation Therapy SPD602, Deferasirox - Transfusional Iron Overload, Iron Overload | Phase 2 | Withdrawn | Shire | 2014-11-20 | 2021-06-02 | |
| Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses Deferasirox - Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2014-02-01 | 2017-04-20 | |
| Allograft for Sickle Cell Disease and Thalassemia Donor Stem Cell Transplantation - Sickle Cell Disease and Thalassemia | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2014-01-01 | 2021-07-29 | |
| Providing Access to Cord Blood Units for Transplants Access to unlicensed cord blood units - Chronic Myelogous Leukemia/Other Leukemia, Acute Leukemias | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2011-10-27 | 2018-12-21 | |
| Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Enriched Hematopoetic Stem Cell Infusion - Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies | Phase 1 / Phase 2 | Withdrawn | Talaris Therapeutics Inc. | 2011-05-01 | 2023-03-03 |
beta-Thalassemia (4) · Anemia, Sickle Cell (2) · Iron Overload (2) · Anemia, Diamond-Blackfan (1) · Bone Marrow Failure Disorders (1) · Hematologic Neoplasms (1) · Iron Metabolism Disorders (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Non-Hodgkin (1) · Lysosomal Storage Diseases (1) · Metabolic Diseases (1) · Multiple Myeloma (1) · alpha-Thalassemia (1)
Anemia (7) · Anemia, Hemolytic (7) · Anemia, Hemolytic, Congenital (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemoglobinopathies (7) · Nutritional and Metabolic Diseases (3) · Bone Marrow Diseases (2) · Metabolic Diseases (2) · Anemia, Aplastic (1) · Anemia, Hypoplastic, Congenital (1) · Blood Protein Disorders (1)
Deferasirox (2) · BID protein, human (1) · SP-420 (1) · VIT-2763 (1)
Abfero Pharmaceuticals, Inc (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · Shire (1) · Talaris Therapeutics Inc. (1) · University of Texas Southwestern Medical Center (1) · Vifor (International) Inc. (1)
United States (3) · Bulgaria (1) · Canada (1) · Israel (1) · Lebanon (1) · Thailand (1) · Turkey (Türkiye) (1)
Ali Taher, MD, PhD (1) · Prapti Patel, MD (1) · Ronald E Gress, M.D. (1) · Suzanne T Ildstad, MD (1)